Isolere Bio by Donaldson launches research-grade IsoTag™ AAV reagent for non-chromatographic cell and gene therapy purification & manufacturing optimization.

Donaldson Co. announces its Isolere Bio and Univercells Technologies businesses are developing an integrated platform for lentivirus manufacturing.

We are excited to have all our submitted presentations and posters be accepted! If attending the American Chemical Society come see us…

Lentiviral vectors (LVs) are widely used viral vectors necessary for the production of several commercial cell and gene therapies. However, their innate fragility and cytotoxicity, due to their lipid bilayer and VSVG (vesicular stomatitis virus envelope glycoprotein) pseudotype, respectively, means that the manufacturing cost of these vectors is extremely high. Traditional downstream purification strategies are being commercially adapted for large and complex viruses.

This interview features: Kelli Luginbuhl, Founder, Business Leader, Isolere Bio by Donaldson, from BioProcess International 2023.

MINNEAPOLIS (February 21, 2023) — Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, today announced the acquisition of (Isolere), an early-stage biotechnology company that develops novel and proprietary IsoTag™ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Isolere enters into an agreement with Oxford Biomedica to develop next-generation manufacturing solutions for lentiviral vectors.

Isolere Bio receives a Phase I SBIR award from NIH to support application of the IsoTag technology to lentivirus manufacturing